The compelling need to provide adoptive cell therapy (ACT) to an increasing number of
oncology patients within a meaningful therapeutic window makes the development of an …

T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has
shown tremendous promise for the treatment of B cell malignancies. The successful …

An emerging approach for treating cancer involves programming patient-derived T cells with
genes encoding disease-specific chimeric antigen receptors (CARs), so that they can …

Chimeric antigen receptor (CAR) T‐cell therapy is a new successful treatment for refractory
B‐cell leukemia. Successful therapeutic outcome depends on long‐term expression of CAR …

Recent clinical successes of chimeric antigen receptor (CAR) T cell therapy have led the
booming of developments in cancer immunotherapy utilizing ex vivo engineered immune …

Genetically engineered T cells have sparked interest in advanced cancer treatment,
reaching a milestone in 2017 with two FDA-approvals for CD19-directed chimeric antigen …

Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …

Novel cell therapies derived from human T lymphocytes are exhibiting enormous potential in
early-phase clinical trials in patients with hematologic malignancies. Ex vivo modification of …

The promising clinical results obtained with engineered T cells, including chimeric antigen
receptor (CAR) therapy, call for further advancements to facilitate and broaden their …

Engineering chimeric antigen receptors (CAR) or T cell receptors (TCR) helps create
disease-specific T cells for targeted therapy, but the cost and rigor associated with …